Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma
Journal of Cancer Research and Clinical Oncology · 17.05.2024 · 150 (5)
DOI: 10.1007/s00432-024-05793-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 17.05.2024. Verfasst von Huilai Lv und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, NO.12, JianKang Road, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophagectomy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Hebei Province, government-funded clinical medical talent training project of Hebei Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Neoadjuvant chemotherapy (NCT) is the standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (ESCC). Some studies reported neoadjuvant immunochemotherapy (NICT) could improve pathological response with manageable safety. However, few studies have compared the efficacy and safety of NICT and NCT, especially survival outcomes. In this study, we compared the efficacy and safety of NICT and NCT after a median follow-up of 36.0 months.
Methods
This was a retrospective study with a 1:1 propensity score matching (PSM). Locally advanced ESCC patients treated with neoadjuvant sintilimab plus chemotherapy or chemotherapy followed by esophagectomy were reviewed. The primary outcome was recurrence-free survival (RFS).
Results
Forty-five patients were identified in each group by PSM. The pathological complete response (pCR) rate in NICT and NCT group were 28.9% and 8.9% (P = 0.02). The hazard ratio (HR) was 0.396 (95% CI 0.171–0.919, p = 0.025) for RFS and 0.377 (95% CI 0.145–0.981, p = 0.038) for overall survival (OS), 3-year RFS was 80.6% and 62.1%, 3-year OS was 86.2% and 68.1%. Patients with pCR, MPR or downstaging had better 3-year RFS and 3-year OS. The incidences of postoperative complications and treatment-related adverse events (TRAEs) were similar.
Conclusion
This trial preliminarily shows that NICT improves pathological and survival outcomes over NCT for resectable locally advanced ESCC, with acceptable and manageable safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, NO.12, JianKang Road, Shijiazhuang, Hebei, China.
- Hebei Key Laboratory of Accurate Diagnosis and Comprehensive Treatment of Esophageal Cancer, Shijiazhuang, Hebei, China.
- Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, NO.12, JianKang Road, Shijiazhuang, Hebei, China. tianziqiang@hebmu.edu.cn.
- Hebei Key Laboratory of Accurate Diagnosis and Comprehensive Treatment of Esophageal Cancer, Shijiazhuang, Hebei, China. tianziqiang@hebmu.edu.cn.
Förderung
- the Natural Science Foundation of Hebei Province
- government-funded clinical medical talent training project of Hebei Province
Zitieren
APA
Lv, H., Zhang, F., Huang, C., Xu, S., Li, J., Sun, B., Gai, C., Liu, Z., Wang, M., Li, Z., & Tian, Z. (2024). Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 150(5). https://doi.org/10.1007/s00432-024-05793-4
Vancouver
Lv H, Zhang F, Huang C, Xu S, Li J, Sun B, et al. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology. 2024;150(5). doi:10.1007/s00432-024-05793-4
BibTeX
@article{Lv2024,
author = {Lv, Huilai and Zhang, Fan and Huang, Chao and Xu, Shi and Li, Jiachen and Sun, Bokang and Gai, Chunyue and Liu, Zhao and Wang, Mingbo and Li, Zhenhua and Tian, Ziqiang},
title = {Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {5},
doi = {10.1007/s00432-024-05793-4}
}
EUVIMED